Overview
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Eligibility
Inclusion Criteria:
- Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification).
- Measurable target disease assessed by the investigator according to RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Exclusion Criteria:
- NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma).
- Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
- Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed > 12 months before treatment.
- Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented > 6 months before starting study treatment.
Other protocol-defined inclusion/exclusion criteria apply.